Novavax, Inc.

NASDAQ:NVAX   3:59:56 PM EDT
16.49
-0.34 (-2.02%)
Other Pre-Announcement

Novavax Reports Q3 Loss Of $2.15 Per Share

Published: 11/08/2022 22:55 GMT
Novavax, Inc. (NVAX) - Quarterly Revenue $735 Million Versus $ 179 Million.
Quarterly and Diluted Loss per Share $2.15.
Novavax - Refining Full Year 2022 Total Revenue Guidance to Approximately $2.0 Billion.
Novavax - Q3 Revenue Includes $628 Million of Revenue Comprised of $626 Million of Product Sales From Nvx-cov2373 Based on the Sale of 35 Million Doses Sold by Novavax.
Novavax - Cash, Cash Equivalents and Restricted Cash Were $1.3 Billion As of September 30, 2022.
Novavax - Delivered Over 94 Million Doses of Nvx-cov2373 Globally to Date.
Further Company Coverage: Nvaxo ((reuters.
Briefs@thomsonreuters.
Com;)).